Navigation Links
ChromaDex Commences a Clinical Trial on pTeroPure™ Pterostilbene
Date:9/7/2010

ed in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to: the ability to market, produce and sell the referenced ingredients; risks relating to product and customer demand, market acceptance of our products; the effect of economic conditions both nationally and internationally; the ability to protect our intellectual property rights; the impact of any litigation or infringement actions brought against us; competition from other providers and products; risks in product development; our ability to raise capital to fund continuing operations; the ability to complete transactions; and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.Investor Inquiries:Liviakis Financial Communications, Inc.John M. Liviakis, President415-389-4670John@Liviakis.comMedia Inquiries:Megan LavineCanale Communications619-849-5388Megan@canalecomm.com
'/>"/>
SOURCE ChromaDex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ChromaDex Announces Second Quarter 2008 Financial Results
2. ChromaDex Announces 2008 Year End Financial Results
3. ChromaDex Launches pTeroPure Pterostilbene
4. GSI Group Accepts Shares in Tender Offer for Excel Technology and Commences Subsequent Offering Period
5. Phase 1b/2a Program Commences for RVX-208
6. Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate
7. Lilly Commences Cash Tender Offer for ImClone Systems at $70 Per Share
8. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
9. SenesTech, Inc. Commences Product Registration Process With Australian Government
10. GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc.
11. BVF Acquisition LLC, a Wholly-Owned Subsidiary of Biotechnology Value Fund, L.P., Commences Tender Offer for Any and All Outstanding Shares of Avigen at $1.00 Per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... astronaut Scott Kelly , who is making final preparations ... and working on the International Space Station, will be available ... Monday, March 9. Kelly will participate from ... of his training. The interviews will be preceded at 5 ... training and previous spaceflights. To schedule an interview, ...
(Date:3/3/2015)... DUBLIN , Mar. 03, 2015 Research and ... addition of the "Gene Therapy Market, 2015 - ... The "Gene Therapy Market, 2015-2025" report provides an extensive ... lot of research has been carried out in this ... five approved therapies (four available in Asian markets; one ...
(Date:3/3/2015)... , March 3, 2015 Adaptive Biotechnologies announced ... is joining its Board of Director as Chair of ... at Zillow Group, Chad oversees all finance, treasury and ... the company,s core finance, treasury and accounting functions, and ... nine acquisitions. In 2013, he was named Puget Sound ...
(Date:3/3/2015)... , March 3, 2015  Regenicin, Inc. (OTC ... specializing in the development of and commercialization of regenerative ... and organs, announced today that it has received the ... Amarantus Bioscience Holdings, Inc. (OTC Bulletin Board: ... Agreement, Amarantus made the final payments due to Regenicin ...
Breaking Biology Technology:NASA Astronaut Scott Kelly Available for Interviews before One-Year Space Station Mission 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 3Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 5Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 6Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 7Adaptive Biotechnologies adds Chad Cohen, Zillow Group CFO, to Board of Directors 2Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 2Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 3
... in Second Pivotal Clinical Trial , WASHINGTON, Nov. ... today announced positive results from BLISS-76, the second of ... for treating systemic lupus. A full presentation of ... Annual Scientific meeting of the American College of Rheumatology. ...
... powder from her ring into wine glasses carelessly left unattended. ... holding a cabochon or faceted gemstone that can be broken ... so large it is rather odd nobody seems to notice ... the "smart capsule" devised in Younan Xia,s laboratory at ...
... DIEGO and INDIANAPOLIS, Oct. 30, 2009 Amylin Pharmaceuticals, Inc., ... LLY ) today announced that the U.S. Food and ... (exenatide) injection. BYETTA is now approved for use as a ... glycemic control in adults with type 2 diabetes. Previously, it ...
Cached Biology Technology:Promise of a New Lupus Treatment Is a Groundbreaking Achievement 2Promise of a New Lupus Treatment Is a Groundbreaking Achievement 3An exquisite container 2An exquisite container 3An exquisite container 4An exquisite container 5BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 2BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 3BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 4BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 5BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 6BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 7
(Date:2/12/2015)... 2015   MedNet Solutions , a global ... management systems, has recently bolstered its ... iMedNet as the eClinical solution ... healthcare consultants.  Building on the Program,s existing benefits ... numerous co-marketing opportunities), MedNet,s new and improved program ...
(Date:2/5/2015)... Carolina , 5. Februar 2015 /PRNewswire/ ... als spezialisiertes Logistikunternehmen und hat eine neue ... klinische Logistikfirma (Clinical Logistics Organization – CLO) ... neuen Kampagne lautet First , mit ... Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... , January 28, 2015 ... Analysis, Size And Segment Forecasts To 2020 has Been ... IR camera market is expected to reach USD 5.10 ... Grand View Research, Inc. IR cameras help identify the ... are expected to witness surging demand in medical imaging ...
Breaking Biology News(10 mins):MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... new University of Colorado at Boulder study shows the ... populations, findings with implications for the fate of ecological ... also is the first to indicate that at least ... quiet ones, perhaps because of their vocalization pitches, a ...
... The U.S. Environmental Protection Agency has awarded a ... how allergic reactions to food are initiated. The research ... whether pesticides produced in genetically engineered plants can trigger ... each year. The study is funded through EPA,s Science ...
... Utah researchers and their colleagues have identified the gene that ... tumor called paraganglioma (PGL). The gene, called hSDH5, is required ... role in the chemical reactions that take place within cells ... be published in the journal Science , to be ...
Cached Biology News:Noise pollution negatively affects woodland bird communities, says CU-Boulder study 2Noise pollution negatively affects woodland bird communities, says CU-Boulder study 3Scientists discover gene mutation responsible for hereditary neuroendocrine tumor 2Scientists discover gene mutation responsible for hereditary neuroendocrine tumor 3
... An entire pressurized perfusion system ... in physiology, biophysics, electrochemistry, or general ... as little as 100 microliters of ... eight solutions in milliseconds from a ...
Anti-Digoxigenin-AP, Fab fragments; from sheep...
...
... Immunogen: Partially purified ... MA1-710 detects vitamin D receptor (VDR) ... amphibian, and fish tissues. This ... or glucocorticoid receptors. MA1-710 detects ...
Biology Products: